TCL Archive Five-Year Course of Tamoxifen Remains Standard Treatment In HR+ Breast Cancer July 26, 2002
TCL Archive President’s Cancer Panel annual report finds barriers in translational research stall progress. July 8, 2005
TCL Archive President Proposes 2.1% Incerase for NIH, 2.4% Increase for NCI, In Year 2000 Budget February 5, 1999